Clinical trials
Lung Diseases trials in Argentina
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2022 | 1 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Recruiting | 9 |
| Active, not recruiting | 4 |
| Terminated | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 12 |
| Novartis Pharmaceuticals | 5 |
| Pfizer | 4 |
| Bayer | 2 |
| United Therapeutics | 2 |
| Upstream Bio Inc. | 2 |
| Eli Lilly and Company | 1 |
| GlaxoSmithKline | 1 |
| Hoffmann-La Roche | 1 |
| Hospital Universitario La Paz | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases | 37 |
| Respiratory Tract Diseases | 16 |
| Asthma | 14 |
| Bronchial Diseases | 12 |
| Lung Diseases, Obstructive | 10 |
| Pulmonary Disease, Chronic Obstructive | 10 |
| Cardiovascular Diseases | 4 |
| Bronchitis, Chronic | 3 |
| COVID-19 | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
Trials
Showing 76 to 37 of 37. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.